MX2014015271A - Inhibidor de jak1 y jak2. - Google Patents

Inhibidor de jak1 y jak2.

Info

Publication number
MX2014015271A
MX2014015271A MX2014015271A MX2014015271A MX2014015271A MX 2014015271 A MX2014015271 A MX 2014015271A MX 2014015271 A MX2014015271 A MX 2014015271A MX 2014015271 A MX2014015271 A MX 2014015271A MX 2014015271 A MX2014015271 A MX 2014015271A
Authority
MX
Mexico
Prior art keywords
jak2
jak1
inhibitor
inden
imidazo
Prior art date
Application number
MX2014015271A
Other languages
English (en)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2014015271A publication Critical patent/MX2014015271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona un compuesto de amino pirazol, el cual es 3-[(1R)-6-fluoro-2,3-dihidro-1H-inden-1-il]-N-(3-metil- 1H-pirazol-5-il)-3H-imidazo[4,5-b]piridin-5-amina, o una sal farmacéuticamente aceptable del mismo, que inhibe JAK1 y JAK2 y, por lo tanto, puede ser útil para tratar cáncer.
MX2014015271A 2012-06-14 2013-06-05 Inhibidor de jak1 y jak2. MX2014015271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659679P 2012-06-14 2012-06-14
PCT/US2013/044211 WO2013188184A1 (en) 2012-06-14 2013-06-05 Inhibitor of jak1 and jak2

Publications (1)

Publication Number Publication Date
MX2014015271A true MX2014015271A (es) 2015-03-05

Family

ID=48626679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015271A MX2014015271A (es) 2012-06-14 2013-06-05 Inhibidor de jak1 y jak2.

Country Status (14)

Country Link
US (1) US9062050B2 (es)
EP (1) EP2861231B1 (es)
JP (1) JP6092376B2 (es)
KR (1) KR20150008907A (es)
CN (1) CN104349775B (es)
AU (1) AU2013274641B2 (es)
BR (1) BR112014030651A2 (es)
CA (1) CA2871659C (es)
EA (1) EA201492104A1 (es)
ES (1) ES2605827T3 (es)
IN (1) IN2014MN02228A (es)
MX (1) MX2014015271A (es)
WO (1) WO2013188184A1 (es)
ZA (1) ZA201407940B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115141195B (zh) * 2021-03-03 2024-02-06 成都先导药物开发股份有限公司 一种nuak抑制剂及其用途
US20230146125A1 (en) * 2021-11-09 2023-05-11 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
CN104349775B (zh) 2017-06-06
AU2013274641A1 (en) 2014-11-20
JP6092376B2 (ja) 2017-03-08
KR20150008907A (ko) 2015-01-23
EA201492104A1 (ru) 2015-06-30
CN104349775A (zh) 2015-02-11
AU2013274641B2 (en) 2015-09-24
WO2013188184A1 (en) 2013-12-19
US20150133490A1 (en) 2015-05-14
IN2014MN02228A (es) 2015-07-17
JP2015519396A (ja) 2015-07-09
BR112014030651A2 (pt) 2017-06-27
ZA201407940B (en) 2016-05-25
CA2871659A1 (en) 2013-12-19
EP2861231B1 (en) 2016-08-31
CA2871659C (en) 2017-04-04
EP2861231A1 (en) 2015-04-22
ES2605827T3 (es) 2017-03-16
US9062050B2 (en) 2015-06-23

Similar Documents

Publication Publication Date Title
MX2014015271A (es) Inhibidor de jak1 y jak2.
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
PH12014501986A1 (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MX354509B (es) Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos.
MY164705A (en) Imidazo [4,5-c] quinolin - 2 - one compound and its use as pi3 kinase / mtor dual inhibitor
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX355728B (es) Inhibidores de cinasas.
AU2012250958A8 (en) Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
HK1183868A1 (zh) 單獨的和與 抑制劑相組合的 刺激劑、 活化劑用於治療系統性硬化症 的用途
MX2018003861A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
MX2013015357A (es) Terapia de combinacion.
MX2013006184A (es) Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
AP3582A (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases